1. Home
  2. BENF vs GLMD Comparison

BENF vs GLMD Comparison

Compare BENF & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BENF
  • GLMD
  • Stock Information
  • Founded
  • BENF 2003
  • GLMD 2000
  • Country
  • BENF United States
  • GLMD Israel
  • Employees
  • BENF N/A
  • GLMD N/A
  • Industry
  • BENF Blank Checks
  • GLMD Biotechnology: Pharmaceutical Preparations
  • Sector
  • BENF Finance
  • GLMD Health Care
  • Exchange
  • BENF Nasdaq
  • GLMD Nasdaq
  • Market Cap
  • BENF 4.6M
  • GLMD 4.5M
  • IPO Year
  • BENF N/A
  • GLMD 2014
  • Fundamental
  • Price
  • BENF $0.44
  • GLMD $2.70
  • Analyst Decision
  • BENF
  • GLMD
  • Analyst Count
  • BENF 0
  • GLMD 0
  • Target Price
  • BENF N/A
  • GLMD N/A
  • AVG Volume (30 Days)
  • BENF 199.2K
  • GLMD 21.6K
  • Earning Date
  • BENF 02-13-2025
  • GLMD 04-03-2025
  • Dividend Yield
  • BENF N/A
  • GLMD N/A
  • EPS Growth
  • BENF N/A
  • GLMD N/A
  • EPS
  • BENF N/A
  • GLMD N/A
  • Revenue
  • BENF N/A
  • GLMD N/A
  • Revenue This Year
  • BENF N/A
  • GLMD N/A
  • Revenue Next Year
  • BENF $6.38
  • GLMD N/A
  • P/E Ratio
  • BENF N/A
  • GLMD N/A
  • Revenue Growth
  • BENF N/A
  • GLMD N/A
  • 52 Week Low
  • BENF $0.43
  • GLMD $2.24
  • 52 Week High
  • BENF $14.16
  • GLMD $23.80
  • Technical
  • Relative Strength Index (RSI)
  • BENF 27.94
  • GLMD 49.41
  • Support Level
  • BENF $0.43
  • GLMD $2.24
  • Resistance Level
  • BENF $0.50
  • GLMD $2.72
  • Average True Range (ATR)
  • BENF 0.05
  • GLMD 0.20
  • MACD
  • BENF -0.01
  • GLMD 0.02
  • Stochastic Oscillator
  • BENF 2.06
  • GLMD 71.47

About BENF Beneficient

Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and an innovative financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.

About GLMD Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Share on Social Networks: